

BAB 5

KESIMPULAN DAN SARAN

5.1 Kesimpulan

Berdasarkan kajian literatur yang dilakukan pada 12 artikel ilmiah maka dapat ditarik kesimpulan bahwa dosis chlorpromazine pada pasien skizofrenia dapat diberikan dengan rentang 100 – 1000 mg/hari P.O dimulai dengan dosis awal rendah 1 x 100 mg/hari P.O. kemudian dosis dapat ditingkatkan bertahap sampai dosis optimal dengan maksimal dosis 1000 mg per hari sesuai kondisi pasien.

Durasi dalam terapi minimal 4 – 8 minggu kemudian jika masih terjadi kekambuhan bisa digunakan terapi jangka panjang sampai 5 tahun bahkan seumur hidup. Efek samping yang sering ditemukan baik dari Asia, Eropa dan Afrika adalah ekstrapiramidal.

5.2 Saran

1. Perlu dilakukan penelitian lebih lanjut mengenai efektivitas chlorpromazine dibanding antipsikotik generasi terbaru.
2. Perlu dilakukan kajian lebih dalam untuk mencegah timbulnya efek samping yang tinggi pada penggunaan chlorpromazine.

DAFTAR PUSTAKA

- Abadi, K., Widiasih, N., Kusumaningrum, P., & Nasrun, M. W. 2018. Penggunaan Antipsikotik pada Lansia dan Efek Kardiovaskular: Evidence Based Case Report. *Journal Of The Indonesian Medical Association*, **68**: 481-485.
- Agarwal, S. M., Bose, A., Shivakumar, V., Narayanaswamy, J. C., Chhabra, H., Kalmady, S. V., Varambaly, S., Nitsche, M. A., Venkatasubramanian, G., Gangadhar, B. N. 2016. Impact of antipsychotic medication on transcranial direct current stimulation (tDCS) effects in schizophrenia patients. *Psychiatry research*, **235**: 97-103.
- American Psychiatric Association. 2010. PRACTICE GUIDELINE FOR THE Treatment of Patients With Schizophrenia Second Edition
- American Psychiatric Association. 2013. Diagnostic and Statistical Manual of Mental Disorder Edition (DSM-V). Washington: American Psychiatric Publishing.
- American Society of Health System Pharmacists. 2011. AHFS Drug Information. United States of America.
- Amir & Nurmiaiti. 2008. RE: Pengenalan Instrument PANSS
- Anggai, M. 2020. The Relationship Between The Nurses Performance And The Patients Families' Satisfaction At Abepuramental Hospital In Jayapura City. *Journal of Critical Reviews*, **7**: 2411-2415.
- Aryani, F., & Sari, O. 2016. Gambaran pola penggunaan antipsikotik pada pasien skizofrenia di ruang rawat inap rumah sakit jiwa. *Jurnal Manajemen dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice)*, **6**: 35-40.
- Bahta, M., Berhe, T., Russom, M., Tesfamariam, E. H., & Ogbaghebriel, A. 2020. Magnitude, Nature, and Risk Factors of Adverse Drug Reactions Associated with First Generation Antipsychotics in Outpatients with Schizophrenia: A Cross-Sectional Study. *Integrated Pharmacy Research & Practice*, **9**, 205.
- Balu, D. T. 2016. *The NMDA Receptor and Schizophrenia. Advances in Pharmacology*, 351–382.

- Boyd-Kimball, D., Gonczy, K., Lewis, B., Mason, T., Siliko, N., & Wolfe, J. 2018. Classics in chemical neuroscience: chlorpromazine. *ACS chemical neuroscience*, **10**: 79-88.
- Cahaya, N., Nasution, R., Fhory, B. N., & Lingga, H. N. 2020. Studi Deskriptif Dua Kombinasi Antipsikotik dan Sindrom Parkinsonisme Dalam Pengobatan Skizofrenia Paranoid. *In Prosiding Seminar Nasional Lingkungan Lahan Basah*, **5(3)**: 194-198.
- Chaula, A., & Mamfaluti, T. 2017. Perbandingan Antara Penggunaan Antipsikotik Atipikal Terhadap Peningkatan Kadar Gula Darah Sewaktu Pada Pasien Skizofrenia di BLUD RSJ Aceh. *Jurnal Ilmiah Mahasiswa Kedokteran Medisia*, **2(1)**.
- Cronin, P., Ryan, F., Coughlan, M. 2008. Undertaking a literature review: a step-by-step approach, *British Journal of Nursing*. **17**: 38-43.
- Demiris, G., Oliver, D. P., & Washington, K. T. 2019. *Defining and Analyzing the Problem. Behavioral Intervention Research in Hospice and Palliative Care*, Academic Press.
- DiPiro, J.T., Wells, B.G., Schwinghammer, T.L., DiPiro, C.V., 2017, *Pharmacotherapy Handbook Tenth Edition-Section 13 Chapter 68*, The McGraw-Hill Companies, Inc, United States.
- DiPiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin T.D., Ellingrod, V. 2020. *Pharmacotherapy a Pathophysiologic Approach Eleven Edition-Section 9 Chapter 84*, The McGraw-Hill Companies, Inc, United States.
- Dong, M., Zeng, L. N., Zhang, Q., Yang, S. Y., Chen, L. Y., Sim, K., He, Y. L., Chiu, H., Sartorius, N., Tan, C. H., Chong, M. Y., Shinfuku & Xiang, Y. T. 2019. Antipsychotic polypharmacy in older adult asian patients with schizophrenia: research on asian psychotropic prescription pattern. *Journal of geriatric psychiatry and neurology*, **32**: 304-311.
- Elvira, S.D. 2013. *Buku Ajar Psikiatri*. Edisi ke-2. Jakarta: Balai Penerbit FKUI, 173-182.
- Fadilla, A. R., & Puspitasari, R. M. 2016. Evaluasi Ketepatan Penggunaan Antipsikotik Pada Pasien Skizofrenia Rawat Inap. *Sainstech Farma*, **9(1)**.

- Fisher, M. D., Reilly, K., Isenberg, K., & Villa, K. F. 2014. Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy. *BMC psychiatry*, **14**: 1-9.
- Hajj, A., Obeid, S., Sahyoun, S., Haddad, C., Azar, J., Rabbaa Khabbaz, L., & Hallit, S. 2019. Clinical and genetic factors associated with resistance to treatment in patients with schizophrenia: a case-control study. *International journal of molecular sciences*, **20**: 4753.
- Handayani, L., Febriani, F., Rahmadani, A., & Saufi, A. 2015. Faktor risiko kejadian skizofrenia di Rumah Sakit Jiwa Grhasia Daerah Istimewa Yogyakarta (DIY). *Humanitas Jurnal Psikologi Indonesia*, **13**: 135-148.
- Health Council of the Netherlands. 2015. Chlorpromazine - Evaluation of the effects on reproduction, recommendation for classification. The Hague: Health Council of the Netherlands; publication no. 14.
- Hendra, G. A. 2020. Analisis Hubungan Kualitas Hidup Terhadap Penggunaan Kombinasi Obat Antipsikotik Pada Pasien Skizofrenia. *Jurnal Kesehatan dr. Soebandi*, **8**: 128-134.
- Igbinomwanhia, N. G., Olotu, S. O., & James, B. O. 2017. Prevalence and correlates of antipsychotic polypharmacy among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria. *Therapeutic advances in psychopharmacology*, **7**: 3-10.
- Ih, H., Putri, R. A., & Untari, E. K. 2016. Perbedaan Jenis Terapi Antipsikotik Terhadap Lama Rawat Inap Pasien Skizofrenia Fase Akut di RSJD Sungai Bangkong Pontianak. *Jurnal Farmasi Klinik Indonesia*, **5**: 115-112.
- Ikawati, Z. 2014. Farmakoterapi Penyakit Sistem Saraf Pusat. Yogyakarta: Bursa Ilmu.
- Ivanova, S. A., Osmanova, D. Z., Boiko, A. S., Pozhidaev, I. V., Freidin, M. B., Fedorenko, O. Y., Semke, A. V., Bokhan, N. A., Kornetova, E. G., Rakhmazova, L. D., Wilffert, B., Loonen, A. J. 2017. Prolactin gene polymorphism (– 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. *Schizophrenia research*, **182**: 110-114.
- Kay, S. R., Fiszbein, A., & Opler, L. A. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophrenia bulletin*, **13**: 261.

- Kementerian kesehatan RI, 2015. Pedoman Nasional Pelayanan Kedokteran Jiwa. Jakarta: Kementerian Kesehatan.
- Kementerian kesehatan RI, 2018. Laporas Riskesdas 2018.
- Lehman, Anthony F, et al., 2010. Practice Guideline For The Treatment of patients With Schizophrenia. Second edition. American Pyschiatric Association. Amerika.
- Li, H., Shen, Y., Wang, G., Shi, J., Ma, C., Xie, S., Zhang, H., Wang, X., Li, K., Xu, X., & Gu, N. 2018. A 6-week, multicenter, double-blind, double-dummy, chlorpromazine-controlled non-inferiorityrandomized phase iitrial to evaluate the efficacy and safety of quetiapine fumarate (SEROQUEL) extended-release (XR) in the treatment of patients with schizophrenia and acute episodes. *Psychiatry research*, **259**:117-124.
- Maramis WF. 2009. Catatan ilmu kedokteran jiwa. Surabaya: Airlangga University Press, hlm. 276.
- Martin D, Croft J, Pitt A, Strelchuk D, Sullivan S, Zammit S. 2020. Systematic review and meta-analysis of the relationship between genetic risk for schizophrenia and facial emotion recognition. *Schizophr Res*, **218**:7-13.
- Maylani, R. Y., Fadraersada, J., & Ramadhan, A. M. 2018. Studi Pemberian Antipsikotik terhadap Beberapa Jenis Skizofrenia Di RSJD Atma Husada Mahakam Samarinda. In *Proceeding of Mulawarman Pharmaceuticals Conferences*, **8**: 267-275.
- Michael S. Lidow. 2000. Neurotransmitter Receptors in Actions of Antipsychotic Medications *Handbook in Pharmacology and Toxicology*. CRC Press.
- Ming T. Tsuang; Stephen J. Glatt; Stephen V. Faraone. 2019. Schizophrenia (The Facts Series). Oxford University Press.
- Moilanen, J. M., Haapea, M., Jääskeläinen, E., Veijola, J. M., Isohanni, M. K., Koponen, H. J., & Miettunen, J. 2016. Long-term antipsychotic use and its association with outcomes in schizophrenia—the Northern Finland Birth Cohort 1966. *European Psychiatry*, **36**:7-14.
- Morris, B. J., & Pratt, J. A. 2014. Novel treatment strategies for schizophrenia from improved understanding of genetic risk. *Clinical genetics*, **86**: 401-411.

- Nainggolan, N. J., & Hidajat, L. L. 2013. Profil kepribadian dan psychological well-being caregiver skizofrenia. *SOUL: Jurnal Pemikiran dan Penelitian Psikologi*, **6**: 21-42.
- National Center for Biotechnology Information. 2020. PubChem Compound Summary for CID 2726, Chlorpromazine. <https://pubchem.ncbi.nlm.nih.gov/compound/Chlorpromazine>. Diakses 7 oktober 2020)
- National institute of mental health (NIMH). 2018. Mengenal Skizofrenia di terjemahkan oleh Anta Samsara. Jagat jiwa.
- Obermeier, M., Schennach-Wolff, R., Meyer, S., Möller, H.-J., Riedel, M., Krause, D., & Seemüller, F. 2011. *Is the PANSS used correctly? a systematic review*. *BMC Psychiatry*, **11**. doi:10.1186/1471-244x-11-113
- O'Reilly, K., O'Connell, P., Donohoe, G., Coyle, C., O'Sullivan, D., Azvee, Z., Maddock, C., Sharma, K., Sadi, H., McMahon, M., & Kennedy, H. G. 2016. Anticholinergic burden in schizophrenia and ability to benefit from psychosocial treatment programmes: a 3-year prospective cohort study. *Psychological medicine*, **46**: 3199.
- Patel, K. R., Cherian, J., Gohil, K., & Atkinson, D. 2014. Schizophrenia: overview and treatment options. *Pharmacy and Therapeutics*, **39**: 638.
- PDSKJI. 2011. Konsensus Penatalaksanaan Gangguan Skizofrenia.
- Priyanto, B., & Permana, I. 2019. Pengaruh Latihan Asertif Dalam Menurunkan Gejala Perilaku Kekerasan Pada Pasien Skizofrenia: A Literature Review.
- Purwandityo, A. G., Febrianti, Y., Sari, C. P., Ningrum, V. D., & Sugiyarto, O. P. 2018. Pengaruh antipsikotik terhadap penurunan skor the positive and negative syndrome scale-excited component. *Indones J Clin Pharm*, **7**: 19-29.
- Ramdhani, A., Muhammad Ali Ramdhani, M. A., Amin, A.S. 2014. Writing a Literature Review Research Paper: A step-by-step approach. *International Journal of Basic and Applied Science*. **3**: 47-56.
- Rothschild, A. J. 2010. Antipsychotic Medication. London: American Psychiatric Publishing.

- Sachdev, P. S., and Matcheri, S. K. 2010. Secondary schizophrenia. New York: Cambridge University Press.
- Saha, K. B., Bo, L., Zhao, S., Xia, J., Sampson, S., & Zaman, R. U. 2016. Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. *Cochrane Database of Systematic Reviews*.
- Salam R, Budiman R, Bastaman TK, Yuniar S, Damping C, Kusumawardhani A, Purnamawati YD, Widyanto S. 1994. Pedoman Definisi PANSS (Positive and Negative Symptoms Scale). FK Universitas Indonesia Bagian Psikiatri.
- Schatzberg, A. F., & Charles DeBattista, D. M. H. 2015. *Schatzberg's Manual of Clinical Psychopharmacology*. American Psychiatric Pub.
- Stahl, M. Stephen. 2013. Stahl's Essential Psychopharmacology. Fourth Edition. United States: Cambridge University Press.
- Sukhmanjeet K.M., Raman M. Chlorpromazine. Treasure island. (<https://www.ncbi.nlm.nih.gov/>, diakses 18 agustus 2020)
- Takahashi, T., Otsubo, T., Kunisawa, S., Sasaki, N., & Imanaka, Y. 2020. Factors associated with high-dose antipsychotic prescriptions in outpatients with schizophrenia: An analysis of claims data from a Japanese prefecture. *Neuropsychopharmacology Reports*, **40**: 224-231.
- Tanaka, T., M. Tomotake., Y. Ueoka, Y. Kaneda., K. Taniguchi., M. Nakataki., S. Numata., S. Tayoshi., K. Yamauchi, S. Sumitani., T. Ohmori, S. Ueno., & T. Ohmori. 2012. Clinical Correlates Associated with Cognitive Dysfunction in People with Schizophrenia. *Psychiatry and Clinical Neurosciences*. **66**: 491–498.
- Taylor, Dena dan Margaret Procter. 2010. "The Literature Review: A Few Tips on Conducting It" dimuat dalam laman University Toronto Writing Center. <https://advice.writing.utoronto.ca/wp-content/uploads/sites/2/literature-review.pdf>. Diakses pada tanggal: 2 September 2020
- Townsend, M. C. 2009. Psychiatric Mental Health Nursing: Concepts of Care in Evidence-Based Practice, Eds 6. Philadelphia: Davis Company.
- Videbeck, S. L. 2011. Psychiatric mental health nursing (5th ed.). Philadelphia, PA: Lippincott Williams & Wilkins.

- Wubeshet, Y. S., Mohammed, O. S., & Desse, T. A. 2019. Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel Mental Specialized Hospital, central Ethiopia: cross-sectional study. *BMC psychiatry*, **19**: 1-8.
- World Health Organization. Shizophrenia. <http://www.who.int/mediacentre/factsheets/fs397/en/>. Diakses pada tanggal: 20 Juli 2020
- Xu, Q., Wu, X., Li, M., Huang, H., Minica, C., Yi, Z., Wang, G., Shen, L., Xing, Q., Shi, Y., He, L., Qin, S. 2016. Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population. *The pharmacogenomics journal*, **16**: 357-365.
- Yulianti, Y. 2016. Cetak Biru Pelayanan Pasien di Rumah Sakit Jiwa Provinsi Jawa Barat Tahun 2014. *Jurnal Administrasi Rumah Sakit Indonesia*, **vol 1**.
- Yulianty, M. D., Cahaya, N., & Srikartika, V. M. 2017. Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan. *Jurnal Sains Farmasi & Klinis*, **3**: 153-164.
- Zahnia, S., & Sumekar, D. W. 2016. Kajian epidemiologis skizofrenia. *Jurnal Majority*, **5**: 160-166.
- Zulkifli, A., & Febriyana, N. 2017. Efek Penggunaan Obat Antikolinergik Pada Pasien Skizofrenia. *Jurnal Psikiatri Surabaya*, **6**: 1-11.